MX368016B - Derivados de uncialamicina, métodos de sintesis y su uso como agentes antitumor. - Google Patents

Derivados de uncialamicina, métodos de sintesis y su uso como agentes antitumor.

Info

Publication number
MX368016B
MX368016B MX2016001975A MX2016001975A MX368016B MX 368016 B MX368016 B MX 368016B MX 2016001975 A MX2016001975 A MX 2016001975A MX 2016001975 A MX2016001975 A MX 2016001975A MX 368016 B MX368016 B MX 368016B
Authority
MX
Mexico
Prior art keywords
uncialamycin
present disclosure
methods
synthesis
derivatives
Prior art date
Application number
MX2016001975A
Other languages
English (en)
Other versions
MX2016001975A (es
Inventor
Gangwar Sanjeev
S Chowdari Naidu
C Nicolaou Kyriacos
Lu Min
Mandal Debashis
B Poudel Yam
Original Assignee
Univ Rice William M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rice William M filed Critical Univ Rice William M
Publication of MX2016001975A publication Critical patent/MX2016001975A/es
Publication of MX368016B publication Critical patent/MX368016B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En un aspecto, la presente descripción proporciona nuevos análogos de uncialamicina de las fórmulas (I) y (II): (ver Fórmulas) La presente descripción también proporciona novedosas sendas sintéticas para obtener uncialamicina y análogos de la misma. Adicionalmente, la presente descripción también describe métodos para usar la uncialamicina y los análogos de la misma. En otro aspecto, la presente descripción proporciona conjugados de anticuerpo-fármaco que comprenden los compuestos de las fórmulas (I) y (II).
MX2016001975A 2013-08-14 2014-08-14 Derivados de uncialamicina, métodos de sintesis y su uso como agentes antitumor. MX368016B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361865896P 2013-08-14 2013-08-14
US201361868783P 2013-08-22 2013-08-22
US201461937003P 2014-02-07 2014-02-07
PCT/US2014/051127 WO2015023879A1 (en) 2013-08-14 2014-08-14 Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents

Publications (2)

Publication Number Publication Date
MX2016001975A MX2016001975A (es) 2016-11-14
MX368016B true MX368016B (es) 2019-09-13

Family

ID=51453866

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016001975A MX368016B (es) 2013-08-14 2014-08-14 Derivados de uncialamicina, métodos de sintesis y su uso como agentes antitumor.
MX2019010875A MX2019010875A (es) 2013-08-14 2016-02-12 Derivados de uncialamicina, metodos de sintesis y su uso como agentes antitumor.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019010875A MX2019010875A (es) 2013-08-14 2016-02-12 Derivados de uncialamicina, metodos de sintesis y su uso como agentes antitumor.

Country Status (13)

Country Link
US (3) US9777013B2 (es)
EP (1) EP3033346B1 (es)
JP (2) JP6474404B2 (es)
KR (1) KR20160068738A (es)
CN (1) CN105899515B (es)
AU (2) AU2014306592B2 (es)
CA (1) CA2921401A1 (es)
EA (1) EA201690388A1 (es)
ES (1) ES2769876T3 (es)
IL (1) IL244084B (es)
MX (2) MX368016B (es)
SG (2) SG11201601047SA (es)
WO (1) WO2015023879A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX368016B (es) * 2013-08-14 2019-09-13 Univ Rice William M Derivados de uncialamicina, métodos de sintesis y su uso como agentes antitumor.
CN105764491A (zh) 2013-12-09 2016-07-13 度瑞公司 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
EP3353198B1 (en) * 2015-09-23 2020-06-17 Bristol-Myers Squibb Company Glypican-3binding fibronectin based scafflold molecules
KR20180089433A (ko) 2015-12-21 2018-08-08 브리스톨-마이어스 스큅 컴퍼니 부위-특이적 접합을 위한 변이체 항체
US20190218294A1 (en) 2016-09-09 2019-07-18 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
SG11202011739SA (en) 2018-05-29 2020-12-30 Bristol Myers Squibb Co Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making
RS64205B1 (sr) 2018-11-30 2023-06-30 Bristol Myers Squibb Co Antitelo koje sadrži c-terminalnu ekstenziju lakog lanca koja sadrži glutamin, njegovi konjugati, i postupci i primene
JP7514836B2 (ja) 2018-12-12 2024-07-11 ブリストル－マイヤーズ スクイブ カンパニー トランスグルタミナーゼによるコンジュゲーションのための改変抗体、ならびにそのコンジュゲート、方法および用途
CN109928981B (zh) * 2019-04-19 2021-06-11 长沙天赐生物医药科技有限公司 洋浦霉素类似物、制备方法及其应用
US20240377413A1 (en) 2019-09-16 2024-11-14 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
US11027253B2 (en) 2019-09-26 2021-06-08 Chevron Phillips Chemical Company Lp Systems and methods for reducing heat exchanger fouling rate
CN116813627B (zh) * 2023-06-15 2025-08-12 哈药慈航制药股份有限公司 一种天赐霉素类似物及其制备方法和应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
CA2086679A1 (en) 1990-07-05 1992-01-06 Hermanus A. M. Verheul Receptor directed-toxin conjugates
US5281710A (en) 1990-08-01 1994-01-25 The Scripps Research Institute Dynemicin analogs: synthesis, methods of preparation and use
US5162330A (en) 1990-11-05 1992-11-10 Bristol-Myers Squibb Co. Dynemicin c antibiotic, its triacetyl derivative and pharmaceutical composition containing same
JP2985435B2 (ja) 1990-11-05 1999-11-29 ロンザ リミテッド ３−アミノクロトンニトリルの製造方法
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
WO1996003124A1 (en) * 1994-07-27 1996-02-08 California Institute Of Technology Dynemicin analogs
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7183388B2 (en) 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
US20060223114A1 (en) 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
CN1638800A (zh) 2002-01-09 2005-07-13 米德列斯公司 抗cd30的人类单克隆抗体
WO2003104418A2 (en) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
JP4680902B2 (ja) 2003-07-22 2011-05-11 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Ｒｇ１抗体及びその使用
WO2005051976A2 (en) 2003-11-20 2005-06-09 Ansata Therapeutics, Inc. Protein and peptide ligation processes and one-step purification processes
WO2005112919A2 (en) 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
CA2587424A1 (en) 2004-11-16 2006-05-26 Avidia Research Institute Protein scaffolds and uses thereof
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
EP1851251A2 (en) 2005-02-18 2007-11-07 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
CA2598522A1 (en) 2005-02-18 2006-08-24 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (psma)
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR20080032097A (ko) 2005-06-20 2008-04-14 메다렉스, 인코포레이티드 씨디19 항체 및 그의 용도
NZ566395A (en) 2005-09-26 2012-03-30 Medarex Inc Human monoclonal antibodies to CD70
WO2007038868A2 (en) * 2005-10-03 2007-04-12 The University Of British Columbia Novel enediyne compound and uses thereof
CN101360761B (zh) 2005-12-08 2012-09-12 米德列斯公司 抗蛋白质酪氨酸激酶7（ptk7）的人单克隆抗体及其用途
NZ568015A (en) 2005-12-08 2012-03-30 Medarex Inc Human monoclonal antibodies to O8E
EP2338898A1 (en) 2006-03-09 2011-06-29 The Board of Regents of the University of Texas System Compositions and methods related to profiling a plurality of cell lines based on peptide binding
US8524865B2 (en) 2006-05-30 2013-09-03 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
AU2007325952B8 (en) 2006-06-29 2013-06-27 The Board Of Trustees Of The Leland Stanford Junior University Cell-free synthesis of proteins containing unnatural amino acids
NZ574673A (en) 2006-09-08 2012-02-24 Ambrx Inc Site specific incorporation of non-natural amino acids by vertebrate cells
KR20150067395A (ko) 2006-12-01 2015-06-17 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
NZ578354A (en) 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
ES2562790T3 (es) 2007-07-17 2016-03-08 E. R. Squibb & Sons, L.L.C. Anticuerpos monoclonales contra Glipicano-3
US8268970B2 (en) 2007-10-01 2012-09-18 Bristol-Myers Squibb Company Human antibodies that bind mesothelin, and uses thereof
ES2509959T5 (en) 2008-02-05 2024-12-19 Bicyclerd Ltd Methods and compositions
US8450278B2 (en) 2008-10-15 2013-05-28 Board Of Regents, The University Of Texas System MUC18 targeting peptides
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
HRP20170334T1 (hr) 2012-02-13 2017-04-21 Bristol-Myers Squibb Company Spojevi enedina, njihovi konjugati, primjene i metode
US8798431B2 (en) 2012-06-01 2014-08-05 Telefonaktiebolaget L M Ericsson (Publ) Fine-grained optical shuffle interconnect topology migration
MX368016B (es) 2013-08-14 2019-09-13 Univ Rice William M Derivados de uncialamicina, métodos de sintesis y su uso como agentes antitumor.

Also Published As

Publication number Publication date
US10233192B2 (en) 2019-03-19
ES2769876T3 (es) 2020-06-29
US20160185791A1 (en) 2016-06-30
US9777013B2 (en) 2017-10-03
CN105899515A (zh) 2016-08-24
US20180065976A1 (en) 2018-03-08
MX2019010875A (es) 2019-12-19
EP3033346B1 (en) 2020-01-08
MX2016001975A (es) 2016-11-14
US20190382412A1 (en) 2019-12-19
JP2019089804A (ja) 2019-06-13
US10889590B2 (en) 2021-01-12
CN105899515B (zh) 2020-01-14
IL244084A0 (en) 2016-04-21
AU2019204034A1 (en) 2019-07-04
SG10201810067YA (en) 2018-12-28
SG11201601047SA (en) 2016-03-30
AU2014306592B2 (en) 2019-04-04
AU2014306592A1 (en) 2016-03-10
JP2016534105A (ja) 2016-11-04
JP6474404B2 (ja) 2019-02-27
KR20160068738A (ko) 2016-06-15
CA2921401A1 (en) 2015-02-19
EP3033346A1 (en) 2016-06-22
IL244084B (en) 2019-08-29
WO2015023879A1 (en) 2015-02-19
EA201690388A1 (ru) 2016-07-29

Similar Documents

Publication Publication Date Title
MX2019010875A (es) Derivados de uncialamicina, metodos de sintesis y su uso como agentes antitumor.
WO2014197871A3 (en) Antibody-drug conjugates, compositions and methods of use
PH12014501229A1 (en) Antibody-drug conjugates and related compounds, compositions, and methods
JO3773B1 (ar) معدلات p2x7
PH12016500953A1 (en) Tricyclic compounds as anticancer agents
UA116395C2 (uk) ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ
MX2020001262A (es) Compuestos de platino a base de lipido y nanoparticulas.
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
MX2014011583A (es) Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.
UA116239C2 (uk) Нові похідні піридину
PH12015502118A1 (en) Pyridin-4-yl derivatives
PH12015502471A1 (en) Purine derivatives as cb2 receptor agonists
PH12015502665A1 (en) Improvements in or relating to organic compounds
CR20150555A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
CY1121238T1 (el) Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων
MX2015015755A (es) Derivados de perhidroquinoxalina utiles como analgesicos.
EP2824108A4 (en) TETRACYCLIC ANTHRACHINONE DERIVATIVES
MX2015014470A (es) Analogos de combretastatina.
IN2013MU02612A (es)
IN2013DE02958A (es)

Legal Events

Date Code Title Description
FG Grant or registration